Xinfeng Capsule(新风胶囊)for the Treatment of Rheumatoid Arthritis Patients with Decreased Pulmonary Function—A Randomized Controlled Clinical Trial

作     者：万磊 刘健 黄传兵 汪元 谌曦 张皖东 王桂珍 范海霞 葛瑶 陈瑞莲 曹云祥 纵瑞凯 刘天阳 

作者机构：Department of RheumatologyThe First Affiliated Hospital of Anhui University of Chinese Medicine 

出 版 物：《Chinese Journal of Integrative Medicine》 (中国结合医学杂志（英文版）)

年 卷 期：2016年第22卷第3期

页      面：168-176页

核心收录：

学科分类：1008[医学-中药学(可授医学、理学学位)] 1006[医学-中西医结合] 100602[医学-中西医结合临床] 10[医学] 

基　　金：Supported by the Natural Science Foundation of China(No.81403388,81173211) Anhui Province Natural Science Fund Project of China(No.1508085QH159) Key Discipline of Chinese Bi Disease Science Projects,State Administration of Traditional Chinese Medicine(No.30) Anhui College of Traditional Chinese Medicine Science and Technology Innovation Team Project(No.2010TD005) the Fund Supported by Anhui University of Chinese Medicine University(No.2014qn025) 

主　　题：rheumatoid arthritis pulmonary function quality of life Xinfeng Capsule clinical trial 

摘      要：Objective： To determine the effectiveness and safety of Xinfeng Capsules （新风胶囊, XFC） for the treatment of rheumatoid arthritis （RA） patients with decreased pulmonary function. Methods： This was a randomized controlled clinical trial of 80 RA patients. Participants were assigned to the tdal group （40 cases） and the control group （40 cases） by block randomization. The trial group was treated with XFC, three pills each time three times daily for 2 months. The control group was treated with tripterygium glycoside （TPT）, two pills each time three times daily for 2 months. Both groups were followed up after 2 months. The clinical effects, changes in joint and pulmonary function, and quality of life before and after treatment were observed; safety indices were also evaluated. Results： Pain, swelling, tenderness, and duration of morning stiffness of joints were obviously decreased after treatment in both the trial and the control groups compared with baseline （P〈0.01）. Compared with before treatment, hand grip strength increased significantly after treatment in the trial group （P=0.0000）; pulmonary function parameters such as forced expiratory volume in the first second of expiration/forced vital capacity （FEV1/FVC）, 50% of the expiratory flow of forced vital capacity （FEFso）, carbon monoxide diffusing capacity （DLco） were increased （P〈0.01 or P〈0.05）; measures of quality of life such as role-physical, body pain, vitality and mental health were also improved after treatment in the trial group （all P〈0.05）. Joint swelling in the trial group decreased compared with the control group （P=0.0043）, while hand grip strength was increased after treatment （P=0.0000）. The increase in FEFs0, DLco, and the dimensions of quality of life such as vitality and mental health were all significantly greater in the trial group than the control group （P〈0.05 or P〈0.01）. Conclusions： XFC not only relieved joint pain in RA patients, but also significantly improved the ventilation and diffusion fu